Treatment of platinum refractory or resistant ovarian cancer.
暂无分享，去创建一个
[1] Marcus Schmidt,et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2018, The Lancet. Oncology.
[2] R. Burger,et al. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses , 2017, Journal of the National Cancer Institute.
[3] R. Giavazzi,et al. Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists , 2017, Angiogenesis.
[4] Gordon C Jayson,et al. Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.
[5] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[6] M. Parmar,et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. , 2014 .
[7] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Ferrero,et al. Sorafenib for ovarian cancer , 2013, Expert opinion on investigational drugs.
[9] A. Mantovani,et al. Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. , 2015, Advances in cancer research.